Latest Views & News

Accrol – following last week’s no balance sheet numbers profit warning, what do the interims show?...

By Steve Moore | Tuesday 18 January 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Previously writing on “the UK’s leading independent tissue converter” Accrol (ACRL), last week with the shares falling to 25p I noted a further profit warning and a “strategic review” despite it arguing ‘timing issues’ and asked why no balance sheet numbers?. Now half-year results…

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



That Was the Week that Was

|